Pharvaris N.V. (PHVS) - Stock Analysis
Last updated: Apr 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Large cash buffer ⢠High cash burn ⢠No reported revenue PHVS is a pre-revenue, research-stage company burning cash (FY net loss $175.7M; NCFO -137.1M) but with a sizable cash buffer ($291.7M) and minimal debt, giving ~2 years' simple runway while the market values it at $1.86B (P/B ~5.97) on future potential.
Price Behavior
Key Price Behavior Insights: ⢠Peak-to-fade ⢠Mid-25s support ⢠28.3â29.5 resistance Support Level: $25.34â$25.42 Resistance Level: $28.30â$29.45 PHVS showed only a modest net gain over the last month with a peak-to-fade from $29.45 to $26.63 signaling short-term weakness and support near the mid-$25s limiting downside absent new catalysts.
Sentiment & News
Key News Insights: ⢠Phase 2 publications ⢠Institutional buying ⢠High analyst targets Pharvaris' MarchâApril 2026 catalysts â Lancet Haematology Phase 2 deucrictibant publications, a business update toward commercialization, institutional buying, and bullish analyst targets implying ~60% upside â point to clinical validation and renewed investor optimism.
AI Summary
Pharvaris has moved from a longâdated discovery bet to a shortâhorizon, binary risk/reward trade where H1â2026 NDA timing and the CHAPTERâ3 prophylaxis readout in 3Qâ2026 will largely determine whether current valuation is justified or collapses. The key actionable point: monitor NDA acceptance/feedback, CHAPTERâ3 topline, and any partner/milestone financing (needed before midâ2027) â positive outcomes should drive rapid upside, while mixed/negative results or a dilutive raise will likely inflict steep downside.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Closed | -6.4% |